Non-Hodgkin Lymphoma Therapeutics Market Size (2024 - 2029)

The non-Hodgkin lymphoma therapeutics market is poised for significant growth, driven by an increasing burden of the disease, a demand for innovative treatments, and a rise in regulatory approvals for new therapies. Despite the initial adverse impacts of the COVID-19 pandemic on market expansion, the market has experienced a positive shift and is expected to continue its upward trajectory. However, the high cost of treatments and stringent regulatory guidelines pose challenges to market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Oncology Drugs Research Non-Hodgkin Lymphoma Therapeutics Industry Market Size

Market Size of Non-Hodgkin Lymphoma Therapeutics Industry

Non-Hodgkin Lymphoma Therapeutics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 7.40 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Non-Hodgkin Lymphoma Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Non-Hodgkin Lymphoma Therapeutics Market Analysis

The non-Hodgkin lymphoma therapeutics market is expected to register a CAGR of nearly 7.4% during the forecast period.

  • The COVID-19 pandemic had some adverse impacts on market growth, as stated by the effects shown in various research studies. For instance, in August 2021, a research study published in BMC Infectious Diseases stated that non-Hodgkin's lymphoma presents a dilemma to healthcare professionals as there is concern that chemotherapeutic and immunosuppressive treatment which is a pillar of cancer therapy, may lead to a worsening of comorbid COVID-19 infections. Similarly, another research study published in August 2021 in the American Society of Hematology stated that patients diagnosed with B-cell non-Hodgkin's lymphoma (B-NHL) are at risk of severe COVID-19 disease and effective vaccination against SARS-CoV-2 may help protect patients with lymphoma against COVID-19. However, the intrinsic immune deficiency associated with B-NHL, as well as the anti-lymphoma treatment itself, may hamper responsiveness to vaccinations. Such studies provide insight into the adverse impact of COVID-19 on non-Hodgkin lymphoma therapeutics market growth during the initial pandemic. However, the market has seen a positive shift in the late pandemic and is expected to grow significantly over the forecast period.
  • Certain factors that are driving the market growth include the growing burden of non-Hodgkin lymphoma (NHL), demand for innovative drugs and novel technologies, and an increase in the number of regulatory approvals for NHL therapy drugs. According to the study published in the American Society of Hematology in November 2022, it is estimated that 779,000 new NHL cases were projected to occur by 2040, with an increase of 43% increase from 2020. Therefore, the rising burden of the NHL is expected to drive market growth due to the rising adoption of NHL therapeutics.
  • The rising approvals of drugs for the NHL are also expected to drive market growth. For instance, in November 2022, the United States Food and Drug Administration (FDA) accepted for Priority Review the Biologics License Application (BLA) for Genmab's subcutaneous epcoritamab (DuoBody-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. In addition, in January 2022, a new gene therapy treatment named Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with diffuse large B-cell lymphoma received marketing authorization in the European Union. Such approvals are anticipated to drive the market growth due to accelerated drug discovery, driving the market growth.
  • However, the high cost of NHL drugs and various complications associated with them are acting as major restraints for the non-Hodgkin lymphoma therapeutics market. Additionally, stringent regulatory guidelines are limiting the growth of the market.

Non-Hodgkin Lymphoma Therapeutics Industry Segmentation

Non-hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or just lymphoma) is a type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system. NHL usually starts in lymph nodes or other lymph tissues, but sometimes it can affect the skin.

The non-Hodgkin lymphoma therapeutics market is segmented by type of therapy (chemotherapy, radiation therapy, targeted therapy, and other types of therapies), cell type (B-cell lymphomas and T-cell lymphoma), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.

The report offers the value (USD) for the above-mentioned segments.

By Type of Therapy
Chemotherapy
Radiation Therapy
Targeted Therapy
Other Types of Therapies
By Cell Type
B-cell Lymphomas
T-cell Lymphoma
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Non-Hodgkin Lymphoma Therapeutics Market Size Summary

The non-Hodgkin lymphoma therapeutics market is poised for significant growth, driven by an increasing burden of the disease and a surge in demand for innovative treatments and technologies. The market is experiencing a positive shift following the initial adverse impacts of the COVID-19 pandemic, which had raised concerns about the effects of cancer therapies on COVID-19 infections. The rising incidence of non-Hodgkin lymphoma, coupled with the growing number of regulatory approvals for new therapies, is expected to propel market expansion. Key players in the industry are actively pursuing partnerships and product launches to enhance the availability of advanced treatment options, further fueling market growth.

North America is anticipated to witness robust growth in the non-Hodgkin lymphoma therapeutics market, attributed to the high incidence of the disease and the approval of innovative therapies. The region's market growth is supported by technological advancements and the introduction of novel treatments, such as CAR-T therapies and bispecific antibodies. Despite the high cost of treatments and regulatory challenges, the market remains competitive, with major players like AstraZeneca, Bayer AG, and F. Hoffmann La-Roche Ltd. actively engaging in research and development to bring forth new solutions. The ongoing initiatives and advancements in cancer research are expected to sustain the market's growth trajectory over the forecast period.

Explore More

Non-Hodgkin Lymphoma Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Non-Hodgkin Lymphoma (NHL)

      2. 1.2.2 Demand for Innovative Drugs and Novel Technologies

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of the Drugs Used in NHL Therapy

      2. 1.3.2 Side Effects Associated with NHL Drugs

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Type of Therapy

      1. 2.1.1 Chemotherapy

      2. 2.1.2 Radiation Therapy

      3. 2.1.3 Targeted Therapy

      4. 2.1.4 Other Types of Therapies

    2. 2.2 By Cell Type

      1. 2.2.1 B-cell Lymphomas

      2. 2.2.2 T-cell Lymphoma

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Non-Hodgkin Lymphoma Therapeutics Market Size FAQs

The Global Non-Hodgkin Lymphoma Therapeutics Market is projected to register a CAGR of 7.40% during the forecast period (2024-2029)

AstraZeneca PLC, Bayer AG, F. Hoffmann La-Roche Ltd, Teva Pharmaceutical Industries Ltd and Seagen Inc are the major companies operating in the Global Non-Hodgkin Lymphoma Therapeutics Market.

Non-Hodgkin Lymphoma Therapeutics Market Report Snapshots

Non-Hodgkin Lymphoma Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)